GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy
GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care.
But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity.
This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped.
1. What Are GLP-1 and Incretin Medicines?
GLP-1 stands for glucagon-like peptide-1, a hormone involved in glucose regulation, appetite, satiety and gastrointestinal function.
.png)
Modern incretin medicines imitate or combine hormonal signals involved in energy balance. Depending on the drug, they may activate the GLP-1 receptor, the GIP receptor, the glucagon receptor, or an additional pathway such as amylin signaling.
These medicines can reduce food intake partly by increasing satiety and reducing appetite. They also affect glucose-dependent insulin secretion, glucagon signaling and gastric emptying.
The important distinction is that not every “GLP-1” is actually the same type of drug. Tirzepatide, for example, is a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 receptor agonist. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist and remains investigational as of October 2026.
2. The GLP-1 Family Tree in 2026
The simplest way to understand the landscape is to separate approved medicines from the pipeline.
↔ Swipe the table sideways to see all columns on mobile.
| Medicine | Mechanism | 2026 U.S. status | Key point |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Approved | Wegovy injection and oral Wegovy are approved for weight-management indications; Wegovy also has cardiovascular and MASH indications. Ozempic is the diabetes brand. |
| Tirzepatide | GIP + GLP-1 receptor agonist | Approved | Zepbound is approved for obesity/overweight management and moderate-to-severe OSA in adults with obesity. Mounjaro is the diabetes brand. |
| Liraglutide | GLP-1 receptor agonist | Approved | An established earlier GLP-1 option for obesity management; daily injection. |
| Orforglipron | Oral small-molecule GLP-1 receptor agonist | Approved in 2026 | Foundayo is a once-daily oral GLP-1 option that does not require the fasting procedure used by some peptide-based oral formulations. |
| Wegovy HD | Higher-dose semaglutide | Approved in 2026 | 7.2 mg once weekly is available for certain adults after tolerating the standard 2.4 mg dose. |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational | Phase 3 data show unusually large weight reductions, but it is not yet approved for routine public use. |
| CagriSema | Semaglutide + cagrilintide (amylin analogue) | Investigational | Still under regulatory review in the U.S. as of October 2026; additional Phase 3 data continue to emerge. |
| Survodutide / mazdutide | GLP-1 + glucagon | Investigational | Important pipeline drugs, particularly for metabolic and liver disease research, but not substitutes for approved therapy. |
Dulaglutide deserves a correction here: although dulaglutide is a GLP-1 receptor agonist used for type 2 diabetes, it should not be presented as an FDA-approved obesity medication simply because it belongs to the same pharmacologic class.
3. What Changed in 2025–2026?
Oral semaglutide entered weight-management care
Wegovy oral semaglutide was approved in the United States in December 2025. The current FDA labeling lists a 25 mg once-daily maintenance dose after stepwise escalation. In the OASIS 4 trial, oral semaglutide 25 mg produced a mean weight reduction of about 13.6% under the treatment-policy estimand at week 64, while the trial-product estimand was 16.6%. That distinction matters because different estimands answer different questions about treatment adherence and discontinuation.
Wegovy HD added a 7.2 mg injectable option
In March 2026, the FDA approved 7.2 mg Wegovy HD for certain adults with obesity or overweight and a weight-related condition. The higher dose is not the starting dose. The current label specifies escalation through the standard doses, with 7.2 mg considered only after at least four weeks of tolerating 2.4 mg when additional weight reduction is clinically indicated.
Orforglipron made the oral GLP-1 category much more practical
Foundayo (orforglipron) was FDA-approved on April 1, 2026 for chronic weight management in adults with obesity or adults with overweight plus a weight-related comorbidity.
Unlike peptide-based oral semaglutide, Foundayo is taken once daily with or without food. Its formulation is also chemically different: it is a small molecule rather than a peptide.
Retatrutide became a Phase 3 reality—not a marketed drug
Retatrutide is one of the most closely watched drugs in obesity medicine. In the TRIUMPH-1 Phase 3 trial, the 12 mg group lost an average of 28.3% of body weight at 80 weeks. In the severe-obesity extension, average loss reached about 30% by 104 weeks in the reported subgroup. That is approaching bariatric surgery territory.
Later 2026 data also showed substantial weight and A1C improvements in people with obesity and type 2 diabetes.
CagriSema did not simply “beat everything”
CagriSema combines semaglutide with the amylin analogue cagrilintide. In the 2026 REDEFINE 4 head-to-head trial, CagriSema produced substantial weight loss but did not meet the prespecified non-inferiority endpoint against tirzepatide. Under the treatment-regimen estimand, weight loss was 20.2% with CagriSema versus 23.6% with tirzepatide at 84 weeks.
This is an important reminder: the incretin field is producing both advances and disappointing results.
FDA removed the suicidal-ideation warning from affected GLP-1 labels
In January 2026, the FDA stated that its evaluation did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonist medications and requested removal of that warning from affected labels including Wegovy and Zepbound.
4. How Much Weight Loss Can You Expect?
There is no single “GLP-1 weight-loss number.” Outcomes depend on the medicine, dose, duration, baseline BMI, diabetes status, adherence, treatment discontinuation and lifestyle support.
| Therapy / study | Approximate result reported | How to interpret it |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | 14.9% mean loss at 68 weeks | Major Phase 3 evidence in adults with overweight/obesity without diabetes. |
| Tirzepatide, SURMOUNT-5 | 20.2% vs 13.7% with semaglutide at 72 weeks | Head-to-head trial in adults with obesity without type 2 diabetes. |
| Oral semaglutide 25 mg, OASIS 4 | 13.6% treatment-policy result at week 64 | A useful oral alternative; the trial also reported a larger treatment-product estimand. |
| Orforglipron, Phase 3 | Approximately 12% at the highest studied dose in pivotal obesity data | Important new oral option, but cross-trial comparisons should be made cautiously. |
| Retatrutide 12 mg, TRIUMPH-1 | 28.3% at 80 weeks | Investigational Phase 3 result—not an approved treatment recommendation. |
Do not compare headline percentages without comparing the trial design. A trial using a treatment-product estimand, for example, can report a different number from a treatment-policy estimand. Population characteristics and treatment duration also differ.
5. Cardiovascular Benefits
The most important change in how GLP-1 therapy is understood is that some benefits extend beyond weight reduction.
Semaglutide: SELECT
In the SELECT trial, 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes were randomized to semaglutide or placebo.
The primary major adverse cardiovascular event outcome occurred in 6.5% of participants receiving semaglutide versus 8.0% receiving placebo, corresponding to a hazard ratio of 0.80.
The trial established an important principle: semaglutide can reduce cardiovascular events in an appropriately selected population even when the medication is being framed primarily as obesity treatment.
What this does not mean
It does not mean every GLP-1 drug has identical cardiovascular-outcome evidence, or that a person without cardiovascular disease should assume a proven cardiovascular indication exists for every product.
Outcome data are drug-specific, population-specific and indication-specific.
6. Kidney, Liver and Sleep-Apnea Benefits
Kidney disease: FLOW
The FLOW trial studied semaglutide in people with type 2 diabetes and chronic kidney disease. The primary kidney composite outcome was reduced by 24% with semaglutide versus placebo. Cardiovascular death and all-cause mortality were also lower in the reported trial results.
This is strong evidence for an important kidney benefit in a defined clinical population.
It should not be converted into the claim that “GLP-1 drugs prevent kidney failure in everyone.” Patients with chronic kidney disease still require comprehensive kidney care, including appropriate blood-pressure treatment, glucose management and other evidence-based therapies when indicated.
Liver disease: MASH has moved from theory toward clinical evidence
The 2026 landscape is substantially different from older GLP-1 articles. Wegovy now carries a U.S. indication for noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults, under accelerated approval.
In the ESSENCE Phase 3 trial, semaglutide 2.4 mg produced resolution of steatohepatitis without worsening fibrosis in 62.9% of treated patients versus 34.3% with placebo at the week-72 interim analysis.
Fibrosis improvement without worsening steatohepatitis was also more frequent with semaglutide.
However, this should not be used to claim that every GLP-1 or every glucagon-containing experimental drug has proven MASH efficacy. The evidence must remain tied to the individual drug and trial.
Obstructive sleep apnea
Tirzepatide is FDA-approved for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
In the SURMOUNT-OSA program, tirzepatide reduced apnea-hypopnea index, body weight, hypoxic burden, inflammatory markers and systolic blood pressure compared with placebo.
For patients with obesity and OSA, this creates a new therapeutic option. It does not mean CPAP or other clinically indicated OSA treatments should automatically be abandoned.
7. Brain, Cancer and Other Emerging Evidence
This is where an evidence-based GLP-1 article must slow down.
Cardiovascular, diabetes, weight-management, kidney and selected liver/OSA outcomes have increasingly strong randomized-trial evidence.
Other areas remain much less settled.
Brain and dementia
Observational studies have reported associations between GLP-1 exposure and lower rates of some neurological outcomes. Mechanistic research suggests possible effects on inflammation, vascular biology and metabolic signaling.
That is scientifically interesting. It is not equivalent to proving that GLP-1 drugs prevent or treat dementia.
Large randomized trials are much more important than retrospective associations for answering that question.
Cancer
The same caution applies to cancer claims.
There are biologically plausible pathways linking obesity, insulin resistance, visceral adiposity and chronic inflammation with cancer risk. Some observational studies have reported associations between GLP-1 use and cancer-related outcomes.
But it would be premature to present GLP-1 treatment as a proven anti-cancer therapy.
Other areas under investigation
Researchers are also studying incretin therapies in osteoarthritis, PCOS, substance-use-related outcomes, metabolic liver disease, neurodegeneration and combinations designed to improve muscle preservation.
These subjects belong in the research pipeline unless and until clinical evidence establishes a treatment effect for a specific indication.
8. Who Should Discuss GLP-1 Therapy?
There is no universal “perfect GLP-1 candidate.” The appropriate medication depends on the diagnosis, treatment objective, contraindications, other medications, side effects, access and the evidence for the particular drug.
Common evidence-based reasons to discuss anti-obesity pharmacotherapy include:
✓ Obesity meeting accepted treatment criteria.
✓ Overweight accompanied by a weight-related medical condition.
✓ Type 2 diabetes where weight and glucose goals both matter.
✓ Established cardiovascular disease in populations covered by a relevant semaglutide indication.
✓ Obesity-associated obstructive sleep apnea where tirzepatide may be appropriate.
✓ Selected patients with MASH and appropriate fibrosis stage under current regulatory criteria.
✓ Patients who have not achieved adequate results with lifestyle intervention alone and for whom the benefits of medication outweigh the risks.
The ADA's 2026 recommendations emphasize individualized dosing, tolerability, response and shared decision-making. The maximum labeled dose is not automatically the best dose for every person.
9. Who Should Not Use These Medicines?
The exact contraindications vary by product. The following points are especially important for the major approved therapies.
Personal or family history of medullary thyroid carcinoma
Current U.S. labeling for semaglutide, tirzepatide and orforglipron contraindicates use in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
The boxed warning originates from thyroid C-cell tumor findings in rodents. The human relevance of those findings remains uncertain, but the contraindication is part of current labeling.
Serious hypersensitivity
A previous serious hypersensitivity reaction to the relevant drug or its components is a contraindication.
Severe gastroparesis
Semaglutide, tirzepatide and orforglipron all slow gastric emptying to varying degrees. Current labeling does not recommend these agents in patients with severe gastroparesis.
Pregnancy
Weight loss is not recommended during pregnancy. Current product labeling advises discontinuation when pregnancy is recognized.
Semaglutide is unusually important here because its long half-life leads the current Wegovy label to recommend discontinuing it at least 2 months before a planned pregnancy when used for weight reduction or cardiovascular risk reduction.
Pancreatitis history
A history of pancreatitis is not automatically an FDA-listed contraindication for all products. It is a clinical risk discussion. Acute pancreatitis has been reported with GLP-1 therapies, and suspected pancreatitis warrants prompt evaluation and discontinuation of the relevant drug while the diagnosis is assessed.
Diabetic retinopathy
Rapid improvement in glucose control can temporarily worsen diabetic retinopathy. Patients with significant diabetic retinopathy need appropriate monitoring rather than simplistic “yes/no” treatment decisions.
Eating disorders, frailty and sarcopenia
These are not blanket FDA contraindications, but they are important clinical considerations.
A person who already has severe frailty, undernutrition, significant sarcopenia or an active eating disorder may need a very different treatment strategy from a person with uncomplicated obesity.
The relevant question is not merely “Can this drug make the scale go down?” It is “Can this person lose excess fat while maintaining adequate nutrition and physical function?”
10. Dosing and Dose Escalation
Semaglutide injection — Wegovy
| Stage | Weekly dose |
|---|---|
| Weeks 1–4 | 0.25 mg |
| Weeks 5–8 | 0.5 mg |
| Weeks 9–12 | 1 mg |
| Weeks 13–16 | 1.7 mg |
| Maintenance | 1.7 or 2.4 mg, depending on indication and tolerability |
| Selected adults after tolerating 2.4 mg | Up to 7.2 mg weekly when additional weight reduction is clinically indicated |
The current Wegovy label explicitly allows dose escalation to be delayed when a dose is not tolerated.
Oral semaglutide — Wegovy tablets
| Period | Once-daily dose |
|---|---|
| Days 1–30 | 1.5 mg |
| Days 31–60 | 4 mg |
| Days 61–90 | 9 mg |
| Day 91 onward | 25 mg maintenance |
Tirzepatide — Zepbound
| Stage | Dose |
|---|---|
| Initiation | 2.5 mg once weekly for 4 weeks |
| First maintenance step | 5 mg once weekly |
| Further escalation | Increase by 2.5 mg increments after at least 4 weeks at the current dose when appropriate |
| Weight-management maintenance | 5 mg, 10 mg or 15 mg weekly |
| OSA maintenance | 10 mg or 15 mg weekly |
| Maximum | 15 mg weekly |
Orforglipron — Foundayo
| Stage | Once-daily dose |
|---|---|
| Starting dose | 0.8 mg |
| After at least 30 days | 2.5 mg |
| After at least another 30 days | 5.5 mg |
| Later escalation options | 9 mg, 14.5 mg or 17.2 mg, according to response and tolerability |
| Maximum | 17.2 mg once daily |
The larger lesson is more important than the individual numbers: dose escalation is a tolerability strategy, not a race to the maximum dose.
11. Side Effects and Warning Signs
The common side effects
The most common adverse effects across the major drugs are gastrointestinal:
• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain or discomfort
• Dyspepsia / indigestion
• Reflux or eructation
• Bloating
• Fatigue
These effects often become more noticeable during dose escalation and may improve with time.
Dehydration is more important than many people realize
Persistent vomiting or diarrhea can lead to volume depletion and, in susceptible patients, acute kidney injury.
Someone taking a GLP-1 drug who is unable to keep fluids down, is urinating very little, becomes weak or dizzy, or develops significant worsening symptoms needs medical assessment.
Gallbladder disease
Acute gallbladder events, including gallstones and cholecystitis, have been reported with GLP-1 therapies. Rapid weight reduction itself can also contribute to gallstone risk.
Seek medical assessment for significant or persistent right-upper-abdominal pain, particularly when accompanied by fever, vomiting or jaundice.
Pancreatitis warning signs
Persistent or severe upper-abdominal pain, particularly pain that may radiate to the back and may occur with nausea or vomiting, requires prompt evaluation.
Do not rely on routine laboratory testing alone. The diagnosis of pancreatitis is clinical and laboratory assessment should be guided by symptoms and the treating clinician.
Hypoglycemia
GLP-1 receptor agonism by itself generally carries much less hypoglycemia risk than insulin or sulfonylurea therapy because insulin secretion is glucose-dependent. However, risk can rise substantially when these medicines are combined with insulin or insulin secretagogues such as sulfonylureas.
Hair loss
Hair loss is listed among common adverse reactions in current labels. It may also overlap with the physiological effects of substantial weight loss, inadequate energy or protein intake and nutritional deficiency.
12. Muscle Loss, Lean Mass and Body Composition
This is one of the most important parts of a modern GLP-1 guide.
Large weight-loss studies do not show that GLP-1 therapy simply “melts fat while preserving every gram of muscle.” Lean tissue can fall during substantial weight loss.
At the same time, “lean mass” is not synonymous with “skeletal muscle,” and a reduction in lean mass does not automatically equal sarcopenia.
A 2026 meta-analysis of randomized controlled trials found that lean mass represented roughly 25%–39% of total weight lost with incretin therapies, depending on the medicine. Importantly, the authors also found that proportional lean-mass loss can occur during lifestyle-only weight loss and was lowest when resistance training was integrated into the treatment strategy.
This changes the question.
The goal should not be to eliminate every kilogram of lean-mass loss. The goal is to preserve muscle function, strength and physical performance while reducing excess adiposity.
Who deserves extra attention?
Risk deserves particular attention in people who are older, frail, already undernourished, physically inactive, losing weight very rapidly or starting treatment with low muscle reserve.
13. Protein, Nutrition and Hydration
Appetite suppression can make a calorie deficit almost effortless. That is both the therapeutic advantage and a nutritional challenge.
Protein is important—but one number does not fit everyone
Older-adult nutrition guidance commonly supports protein intakes around 1.0–1.2 g/kg/day for healthy older adults, with higher targets often used when malnutrition risk or illness is present.
For people using appetite-suppressing medication, clinicians and dietitians may choose higher protein targets during active weight loss depending on body size, renal function, age, activity level and clinical context.
There is no universally proven GLP-1-specific protein prescription that should be applied to everyone.
A practical structure
1. Protein at each meal. Avoid relying on one large protein serving at dinner to compensate for a protein-free day.
2. Eat nutrient-dense foods first. Appetite may be too low to “make up” for poor food choices later.
3. Use convenient protein foods when necessary. Yogurt, eggs, fish, lean meats, tofu, legumes or a clinically appropriate protein supplement may help when appetite is low.
4. Do not unintentionally create a starvation diet. The drug is supposed to make eating less easier—not make adequate nutrition impossible.
5. Protect hydration. Especially during dose escalation or episodes of vomiting/diarrhea.
Micronutrients
There is no evidence-based reason to automatically place every GLP-1 user on a large supplement stack.
Instead, think about nutritional adequacy. Calcium, vitamin D, vitamin B12, iron, folate, magnesium and other nutrients may require attention when dietary intake is poor or when an individual already has a deficiency or an increased clinical risk.
Blood testing should be guided by history, symptoms and clinical context rather than by an indiscriminate “GLP-1 blood panel.”
14. Resistance Training and Physical Function
Exercise does not need to become an elite athlete's program.
The key principle is progressive resistance training.
For many adults, two or three well-designed resistance sessions per week can provide a practical foundation. Walking and aerobic exercise remain valuable for cardiovascular fitness, mobility, glucose regulation and general health, but resistance exercise provides a distinct stimulus for muscle and strength.
Simple movement categories
| Movement pattern | Examples |
|---|---|
| Squat | Chair squat, goblet squat, leg press, split squat |
| Hinge | Hip hinge, Romanian deadlift, hip thrust |
| Push | Wall push-up, push-up, chest press, overhead press |
| Pull | Row, resistance-band row, lat pulldown |
| Carry | Farmer carry or suitcase carry |
| Balance | Single-leg stance and other age-appropriate balance work |
Training should be matched to age, mobility, injuries, frailty and previous exercise experience. A person starting from zero does not need to train like someone who has lifted weights for 20 years.
Track strength—not just weight
Useful functional markers can include:
• Ability to rise from a chair
• Walking speed
• Grip strength when clinically appropriate
• Number of repetitions performed safely
• The load used for key exercises
• Everyday physical independence
If body weight is falling while strength, mobility and functional capacity deteriorate substantially, the treatment plan deserves reassessment.
15. Bone Health
Bone health deserves more nuance than the statement “GLP-1 drugs destroy bone.” Current evidence does not justify such a blanket claim.
Substantial weight loss itself can affect bone remodeling, mechanical loading and bone mineral density. Some body-composition studies have also reported changes in bone-related measurements during treatment.
At the same time, fracture outcomes are not uniform across populations and studies. Much of the concern is concentrated in people who already have risk factors such as older age, low body weight, frailty, menopause-related bone loss or osteoporosis.
Practical bone-health priorities
✓ Adequate protein
✓ Adequate dietary calcium
✓ Adequate vitamin D based on individual needs
✓ Resistance exercise
✓ Weight-bearing activity where appropriate
✓ Fall prevention and balance work in older adults
✓ Formal fracture-risk evaluation when clinically indicated
✓ DEXA scanning when appropriate based on age, sex, fracture risk and clinical history—not automatically for every GLP-1 user
16. What Should Be Monitored?
The correct monitoring strategy should be individualized, but a useful framework includes four domains.
| Domain | Examples | Why it matters |
|---|---|---|
| Effectiveness | Weight, waist circumference, glucose/HbA1c where relevant, blood pressure | Confirms whether treatment is achieving its clinical objective. |
| Tolerability | Nausea, vomiting, constipation, diarrhea, abdominal symptoms | May require slower escalation or a different maintenance dose. |
| Nutrition | Protein intake, overall food intake, symptoms of malnutrition | Appetite suppression can unintentionally reduce nutrient intake. |
| Function | Strength, mobility, exercise capacity, falls | Helps distinguish successful fat loss from deteriorating physical reserve. |
Laboratory testing should be based on the individual situation. For example, glucose monitoring is particularly important in people with diabetes, especially when insulin or a sulfonylurea is also being used.
17. GLP-1 Drugs and Surgery/Anesthesia
This issue has evolved quickly.
GLP-1 drugs can delay gastric emptying, and there have been reports of retained gastric contents and pulmonary aspiration during anesthesia or deep sedation.
But the answer is not simply “everyone must stop the drug for a week.” Modern multi-society guidance emphasizes an individualized risk assessment involving the prescribing clinician, procedural team and anesthesia team.
Factors that may increase concern include:
• Active dose-escalation phase
• Higher doses
• Significant nausea, vomiting, bloating, abdominal pain or constipation
• Known gastroparesis or other conditions that delay gastric emptying
• A procedure involving general anesthesia or deep sedation
Depending on the risk profile, the care team may modify the pre-procedure diet, anesthesia plan, medication schedule or other precautions.
18. Pregnancy and Oral Contraception
Pregnancy
Weight loss is not recommended during pregnancy. Current U.S. labeling advises stopping major approved GLP-1 therapies when pregnancy is recognized.
For semaglutide used for weight reduction or cardiovascular risk reduction, the current Wegovy label recommends discontinuation at least two months before a planned pregnancy.
Oral contraceptives and tirzepatide
Tirzepatide can delay gastric emptying enough to affect absorption of oral hormonal contraceptives. The current Zepbound label advises patients using oral hormonal contraception to switch to a non-oral method or add a barrier method for 4 weeks after treatment initiation and for 4 weeks after each dose escalation.
Orforglipron
The current Foundayo label contains a similar but product-specific recommendation: oral contraceptive users are advised to switch to a non-oral method or add a barrier method for 30 days after initiation and for 30 days after each dose escalation.
These rules are product-specific and should not be generalized from one drug to another.
19. What Happens When You Stop a GLP-1?
This is one of the most important long-term questions.
Obesity is a chronic, relapsing disease. The physiological mechanisms that defend body weight do not disappear simply because a person reaches a target number on the scale.
The 2026 ADA Standards of Care report that discontinuation of semaglutide and tirzepatide can lead to substantial weight recurrence, with clinical-trial modeling suggesting that approximately one-half to two-thirds of the lost weight may return within a year after sudden discontinuation in some study populations.
This does not mean every individual will regain exactly the same amount.
It does mean that maintenance should be planned before treatment begins.
20. The Long-Term Maintenance Strategy
The old concept was:
Take the drug → lose weight → stop the drug.
The newer evidence-based model is closer to:
Assess → treat → preserve function → reassess → maintain using the lowest effective strategy appropriate for the person.
Before starting
Know the treatment target. Is the priority weight, HbA1c, cardiovascular risk, kidney disease, OSA, liver disease—or several of these?
Know the maintenance plan. What happens after the target is reached?
Know the affordability plan. What happens if coverage changes?
Know the nutrition plan. How will adequate protein and micronutrients be maintained?
Know the exercise plan. How will muscle and physical function be preserved?
Know the safety plan. What symptoms require urgent assessment?
During treatment
The ADA 2026 recommendations emphasize assessing effectiveness and safety at least monthly during the first three months and at least quarterly thereafter in obesity pharmacotherapy.
A person who is doing well does not necessarily need the maximum dose. A person who is not responding adequately may need a broader reassessment rather than endless dose escalation.
If the medication must be stopped
The approach should depend on the reason for stopping.
If treatment is stopped because of a serious adverse reaction, the focus is safety and medical evaluation.
If treatment is stopped because the weight-loss goal was reached, a deliberate maintenance strategy becomes more important.
That may involve continued pharmacotherapy, lower effective dosing where appropriate, another evidence-based obesity treatment, structured nutrition support, resistance exercise, behavioral intervention, or in selected patients metabolic surgery.
The appropriate strategy is individualized rather than ideological.
GLP-1 Therapy Is Not Just About “Eating Less”
One reason these medications have had such a large clinical effect is that obesity is not simply a willpower problem.
Body weight is regulated by interacting biological, environmental, behavioral, metabolic and neurological systems. Appetite, satiety, energy expenditure, reward pathways and metabolic adaptation all influence whether weight loss is sustained.
GLP-1 and related therapies change several of these signals at once.
That is why some people experience a remarkable reduction in appetite and why weight loss can continue even after years of unsuccessful dieting attempts.
But the same appetite suppression creates a second challenge:
When the signal to eat is dramatically reduced, nutrition must become intentional.
What a “Good” GLP-1 Outcome Looks Like
A successful treatment result should ideally include more than percentage weight loss.
| Measure | Desired direction |
|---|---|
| Excess body fat | ↓ |
| Waist circumference | ↓ |
| Blood glucose / HbA1c when relevant | ↓ toward individualized target |
| Blood pressure | ↓ when elevated |
| Cardiometabolic risk | ↓ |
| Physical function | → stable or improved |
| Strength | → stable or improved |
| Nutritional adequacy | → maintained |
| Quality of life | ↑ |
This is a better definition of quality weight loss than the largest number on the scale.
21. OneDayMD Evidence Grading
OneDayMD uses an internal evidence framework to distinguish established findings from plausible but unconfirmed claims. These labels are editorial tools, not a formal clinical guideline classification.
| Grade | Meaning | Typical examples in this article |
|---|---|---|
| E5 | High-certainty clinical evidence / regulatory-supported outcome | Selected cardiovascular, obesity, OSA and MASH indications with strong clinical evidence |
| E4 | Strong randomized clinical evidence | Major weight-loss trials, kidney outcomes and major functional outcomes |
| E3 | Moderate clinical evidence | Selected controlled trials and consistent clinical observations |
| E2 | Limited observational or indirect evidence | Some neurological, cancer and other emerging associations |
| E1 | Mechanistic or preclinical rationale | Biological hypotheses for neuroprotection or anti-cancer effects |
| E0 | Unproven / unsupported | Claims that a GLP-1 can cure cancer, reverse aging or guarantee permanent weight loss |
Common GLP-1 Myths—Updated for 2026
Myth 1: “They are just weight-loss drugs.”
Correction: Some GLP-1 and incretin therapies now have evidence or regulatory indications involving cardiovascular disease, kidney disease, MASH, diabetes and obstructive sleep apnea.
Myth 2: “The highest dose is always the best dose.”
Correction: ADA 2026 specifically emphasizes individualized dosing and notes that the optimal dose may be lower than the maximum approved dose.
Myth 3: “All weight lost is fat.”
Correction: Lean mass can also decline during substantial weight loss.
Myth 4: “Lean mass loss means the drug causes sarcopenia.”
Correction: Lean mass and sarcopenia are not the same thing. Strength, performance and clinical function matter.
Myth 5: “GLP-1 drugs automatically cause osteoporosis.”
Correction: Bone effects remain more nuanced. Weight loss itself affects bone physiology, and risk assessment should focus on the individual's fracture and osteoporosis risk.
Myth 6: “You have to stop every GLP-1 before surgery.”
Correction: Contemporary guidance emphasizes individualized perioperative assessment rather than a universal rule for every patient.
Myth 7: “If I stop the drug, the weight is permanently gone.”
Correction: Weight recurrence is common after stopping chronic obesity pharmacotherapy.
Myth 8: “If one experimental GLP-1 works, all the next-generation drugs are better.”
Correction: CagriSema's 2026 head-to-head result is a useful reminder that the field does not move in a straight line.
22. Frequently Asked Questions
What is the strongest GLP-1-type treatment for weight loss?
There is no single universal answer. In a 2025 head-to-head trial in adults with obesity without type 2 diabetes, tirzepatide produced greater average weight loss than semaglutide at 72 weeks. But medication choice should also consider indication, adverse effects, comorbidities, dose tolerance, access and the patient's treatment goals.
Is tirzepatide a GLP-1?
Tirzepatide activates both the GIP and GLP-1 receptors. It is therefore a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 receptor agonist.
What is retatrutide?
Retatrutide is an investigational single molecule that activates the GIP, GLP-1 and glucagon receptors. Phase 3 studies have reported very large weight reductions, but it remains investigational as of October 2026.
Is oral semaglutide now available for obesity?
Yes. Wegovy tablets containing oral semaglutide were FDA-approved in the U.S. in late 2025 for relevant cardiovascular risk-reduction and weight-management indications.
What is the new oral GLP-1 drug in 2026?
Foundayo (orforglipron) was FDA-approved in April 2026 for chronic weight management in adults with obesity or adults with overweight with a weight-related medical condition.
Can GLP-1 drugs cause muscle loss?
Weight loss with incretin therapy can include a meaningful reduction in lean mass. This does not mean every patient develops clinically significant muscle wasting. Protein adequacy, resistance training and monitoring of physical function are important ways to reduce avoidable loss of muscle reserve.
Should everyone taking a GLP-1 get a DEXA scan?
No. DEXA should be based on age, sex, fracture risk, menopausal status, body weight, medical history and clinical judgment rather than automatically ordered for every person taking a GLP-1 medicine.
Can GLP-1 drugs cure cancer?
No. Some cancer-related observational findings and mechanistic hypotheses are interesting, but GLP-1 therapy is not established cancer treatment and should not replace evidence-based oncology care.
Do you need to stop GLP-1 drugs before surgery?
Not automatically. The procedural team should know that you are taking the drug. Current guidance emphasizes assessment of dose-escalation status, gastrointestinal symptoms and other aspiration-risk factors, with individualized management.
What happens when you stop a GLP-1?
Weight recurrence is common. The amount varies among individuals, but randomized-trial evidence shows that substantial weight can return after treatment discontinuation. Maintenance should be planned before treatment begins.
The OneDayMD GLP-1 Framework
1. Match the drug to the problem.
Weight, diabetes, cardiovascular disease, CKD, MASH and OSA are not the same treatment objective.
2. Match the dose to the person.
More is not automatically better.
3. Protect nutrition.
Appetite suppression should not become accidental malnutrition.
4. Protect muscle.
Resistance training and sufficient protein are part of the treatment strategy.
5. Monitor function.
A declining scale with declining strength is not necessarily a successful outcome.
6. Respect the warnings.
Severe abdominal pain, dehydration, persistent vomiting, allergic reactions and concerning perioperative symptoms require appropriate medical attention.
7. Plan maintenance before starting.
GLP-1 therapy for obesity is generally chronic disease management, not a short antibiotic-style course.
8. Separate evidence from hype.
Approved indications, randomized trials, observational signals and laboratory hypotheses should never be presented as though they were equivalent.
23. Selected References & Primary Sources
- American Diabetes Association. Standards of Care in Diabetes—2026, Section 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes. View source
- FDA. Wegovy (semaglutide) Prescribing Information, 2026. Current injection and tablet dosing, cardiovascular indication, MASH indication and safety information. FDA label
- FDA. Wegovy HD approval, March 19, 2026. Approval of the 7.2 mg semaglutide injection for certain adults with obesity or overweight plus a weight-related condition. FDA announcement
- FDA. Zepbound (tirzepatide) Prescribing Information, 2026. Dosing, OSA indication, contraindications, gastrointestinal adverse reactions, pregnancy and oral contraceptive guidance. FDA label
- FDA. Foundayo (orforglipron) Prescribing Information, 2026. Oral GLP-1 dosing, weight-management indication and current safety information. FDA label
- FDA. GLP-1 suicidal-ideation safety review, January 13, 2026. FDA stated that its evaluation did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonist medications. FDA safety communication
- Wilding et al. NEJM. Once-Weekly Semaglutide in Adults with Overweight or Obesity. 2021;384:989–1002. DOI: 10.1056/NEJMoa2032183
- Lincoff et al. NEJM. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. 2023;389:2221–2232. DOI: 10.1056/NEJMoa2307563
- Perkovic et al. NEJM. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. 2024;391:109–121. DOI: 10.1056/NEJMoa2403347
- Packer et al. NEJM. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. 2025;392:427–437. DOI: 10.1056/NEJMoa2410027
- Malhotra et al. NEJM. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. 2024;391:1193–1205. DOI: 10.1056/NEJMoa2404881
- Sanyal et al. NEJM. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. 2025;392:2089–2099. DOI: 10.1056/NEJMoa2413258
- Aronne et al. NEJM. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. 2025;393:26–36. DOI: 10.1056/NEJMoa2416394
- Wharton et al. NEJM. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. 2025;393:1077–1087. DOI: 10.1056/NEJMoa2500969
- Lilly. Retatrutide TRIUMPH-1 Phase 3 results, May 2026. 28.3% average weight loss at 80 weeks with 12 mg in adults with obesity or overweight without diabetes. Lilly release
- Lilly. Retatrutide TRIUMPH-2 results, September 29, 2026. Phase 3 results in adults with obesity or overweight and type 2 diabetes. Lilly release
- Novo Nordisk. CagriSema REDEFINE 4, February 23, 2026. Head-to-head data against tirzepatide at 84 weeks. Novo Nordisk release
- Kindel et al. Multi-society clinical practice guidance for perioperative GLP-1 use. Surgical Endoscopy. 2025;39:180–183. DOI: 10.1007/s00464-024-11263-2
- 2026 systematic review and meta-analysis of lean mass changes with incretin therapy. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.70666
- Emrani A. The GLP-1 Breakthrough: A Cardiologist’s Secrets to Lasting Weight Loss and a Healthier Heart, 2025. Amazon
- Emrani A. Your Updated GLP Manual, 2026. Substack.
.png)
.png)
.png)
.png)
Comments